Review article in a peer-reviewed journal examines studies of GEMTESA published in the past 3 years Data support GEMTESA's role as an effective treatment option for overactive bladder (OAB)
Data from the dedicated, stand-alone, ambulatory blood pressure trial will be the focus of a podium presentation Efficacy in patients with 'dry' overactive bladder, based on a post-hoc analysis
Urovant Sciences Announces Publication of Positive Long-Term Clinical Safety and Efficacy Data on the FDA-Approved Overactive Bladder Therapy, GEMTESA (vibegron), in the Journal of Urology
Urovant Sciences, a wholly owned subsidiary of Sumitovant, announced today that the
Journal of Urology has published positive safety and efficacy data from the GEMTESA (vibegron) double-blind 40-week extension study with patient data over a total exposure of 52 weeks (NCT03583372) in the print version of the
Journal of Urology. The peer-reviewed publication is currently available online and the print article is scheduled to be published in the May issue of the journal.
The published analysis supports the safety and efficacy of GEMTESA for the treatment of overactive bladder (OAB) in patients with symptoms of urge urinary incontinence (UUI), urgency, and urinary frequency.
a service that is going to help was empty cans with a transport most people are suffering every morning waiting for taxes all scrambling for my last year there might be a but then we are going to solve this problem. by. connects motorists who have empty seats never be a cold with passing just wanted to catch a lift into town. payment is done by a mobile money platforms such as mtesa. one kilometer of the journey costs about $3.00 euro cents. this is not too expensive the public transport system costs around 20 louis and flat but it means that i have to go through so much trouble in the morning i have to fight for my place in the taxi so for me it s much better to pay a bit more for better and more reliable service this is much more efficient than